Actively Recruiting
Evaluating Safety and Effectiveness of Bexmarilimab Combined with Doxorubicin in Adults with Metastatic Soft-Tissue Sarcoma
Led by MedSIR · Updated on 2026-08-31
278
Participants Needed
11
Research Sites
13 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the use of bexmarilimab, a CLEVER-1 antibody, combined with doxorubicin chemotherapy in adults with metastatic soft-tissue sarcoma STS. The study aims to analyze both the safetyby identifying toxicities and adverse eventsand the effectiveness of this combination treatment in slowing disease progression or death. This is a Phase IbII trial focused on advanced STS treatment. Participants will receive bexmarilimab and doxorubicin in various dosing regimens. In Phase Ib, different doses of bexmarilimab are tested with doxorubicin to determine the recommended dose for Phase II. In Phase II, participants are randomized to receive either the combination of bexmarilimab plus doxorubicin for six cycles followed by bexmarilimab alone until toxicity or progression, or doxorubicin alone. Treatments are administered intravenously every 21 days. Throughout the study, participants will have regular assessments including monitoring for side effects, disease progression, and survival. Researchers will evaluate progression-free survival and other outcomes such as overall response and duration of response up to 36 months. Blood samples and tumor tissue will be collected for analysis. The study spans up to 36 months for outcome measurements with ongoing treatment and follow-up until disease progression or unacceptable toxicity.
CONDITIONS
Brief Title
A Phase Ib/II Study to Evaluate Safety and Efficacy of Bexmarilimab in Combination With Doxorubicin in Metastatic Soft-tissue Sarcoma.
Research Team
M
MEDSIR
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here